What leaked and why reactions diverged
Snippets of results surfaced on social media days before a planned reveal at the European Society for Medical Oncology meeting in Madrid. The personalized cancer vaccine improved outcomes, reducing the chance tumors return by 42% and cutting the risk of distant spread by 38%.
For melanoma, that is a meaningful step forward and could become an option for many people with high relapse risk after surgery. Results like these often set up approvals, and oncologists cheered. Markets did not. Both stocks fell, and Moderna's drop hit record levels on Thursday.
What doctors saw in the data
Michael Postow, a melanoma specialist at Memorial Sloan Kettering and a study investigator, said, "I am quite impressed," adding, "It is likely that we haven't seen the full therapeutic effect of all of this so far."
Every patient also received Merck's top seller Keytruda, so the vaccine is an add-on. According to Sekwon Jang, who leads melanoma research and therapeutics at the Inova Schar Cancer Institute and served as a trial investigator, that incremental gain along with the lack of serious side effects could persuade more patients. "With this combination I think the risk-benefit ratio actually is much more favorable," he said. "I expect more of my patients will chose to receive this combination treatment," if it is approved.
After decades of disappointment for cancer vaccines that target solid tumors, this could be real progress. Still, the complete dataset needs to be shown to doctors and investors to judge durability and size of benefit.
When markets feel noisy, get clear, concise context fast by signing up for the free Market Briefs
Why Wall Street recalibrated
Even with Thursday's slide, Moderna remains above where it traded before August, when it said the shot succeeded without releasing full details. By 12:36 p.m. Friday in New York, the shares were up 1.7%.
Investors had assumed this would kick off a broader oncology push across lung, bladder and other cancers. Because only limited data were visible, confidence wobbled on how strong the distant-spread benefit really is, and on the company's post Covid plan to become a major cancer player. "While approval seems likely, commercial success is far less certain," wrote RBC Capital Markets analyst Trung Huynh, saying the numbers raise "fundamental questions" about how the vaccine stacks up versus today's gold-standard treatment, a regimen that may deliver comparable benefits at a far lower price.
The road ahead and the investor takeaway
Success in melanoma increases pressure on Moderna and Merck to finish studies in other tumors, even as near term sales and the broader market for the technology remain unclear. Production is another hurdle. At the University of Oxford, associate professor Lennard Lee said, "This is an extraordinarily complex and potentially expensive way to manufacture medicines." He added, "The logistics could make Amazon look simple."
The full results are slated for Saturday in Madrid. The bottom line for your portfolio: clinical momentum looks real, but the size of the oncology opportunity, the economics of bespoke manufacturing, and how the benefit stacks up against today's standard will come into focus only when the full data land.
If you want a calm, daily read that covers economy, stocks and crypto, subscribe to the free Market Briefs newsletter
